Wrap Text
ASPI announces purchase order for enriched barium-137 from a U.S.-based customer
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI ANNOUNCES PURCHASE ORDER FOR ENRICHED BARIUM-137 FROM A U.S.-BASED CUSTOMER
Washington, D.C., September 30, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI
("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in multiple industries, today announced
that it has received a purchase order from a U.S.-based customer for the supply of enriched Barium-
137, with a delivery date during Q1 2026.
Enriched Barium-137: Unlocking Scalable Quantum Computing
The use of high-purity Barium-137 is emerging as a critical enabler of ion-trap quantum computing, one
of the leading approaches to building large-scale quantum machines.
By providing a stable and uniform qubit platform, enriched Barium-137 allows for more reliable operation
of quantum processors and reduces the complexity of control systems. This improved consistency is
essential for scaling from today's small research systems to tomorrow's fault-tolerant quantum
computers capable of solving real-world problems.
In addition, Barium-137's favourable optical properties—operating in accessible visible-light
wavelengths—make it easier to integrate with existing hardware and support future developments in
quantum networking and modular architectures, where multiple processors are linked together to create
more powerful systems.
As demand for larger, commercially viable quantum computers accelerates across industries, enriched
Barium-137 is expected to become a cornerstone material, helping to bridge the gap between laboratory
demonstrations and practical, scalable technologies.
Robert Ainscow, Interim CEO of ASP Isotopes, commented:
"This purchase order for enriched Barium-137 is an important achievement in our strategy to establish
ASP Isotopes as a leading supplier of advanced materials to the quantum computing industry. We
anticipate growing demand from customers as enriched Barium-137 has the potential to be
transformative in enabling scalable architectures. We believe we have the ability to reliably produce and
deliver multiple industrial isotopes, such as Barium-137 and Silicon-28. We are excited about the role
ASP Isotopes can play in supporting cutting-edge technologies and advancing quantum computing from
the laboratory into real-world commercial applications."
Viktor Petkov, Chief Commercial Officer of ASP Isotopes, added:
"This purchase order for enriched Barium-137 is a testament to how our products align with ASP
Isotopes' broader multi-isotope, multi-use, multi-customer electronic gases strategy. This sector is
rapidly evolving into one of the most dynamic and significant growth markets in advanced materials.
Demand for isotopically pure gases and materials now spans quantum computing, semiconductors, AI
capability, data center construction and a wide range of other high-technology applications. By
positioning ourselves at the centre of this expanding supply chain, ASP Isotopes is building a scalable
business model capable of serving multiple industries while supporting the breakthrough technologies
that will shape the future."
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development
of technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities
in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass
(light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging
healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. We believe the ASP technology (Aerodynamic Separation Process) is ideal for enriching
low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements can be identified by words such as "believes," "plans," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of
forward-looking statements include, among others but are not limited to, the commencement of supply
of isotopes to customers, the construction of additional enrichment facilities, and statements we make
regarding expected operating results, such as future revenues and prospects from the potential
commercialization of isotopes, future performance under contracts, and our strategies for product
development, engaging with potential customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict, many of which are outside our control. Our actual
results, financial condition, and events may differ materially from those indicated in the forward-looking
statements based upon a number of factors. Forward-looking statements are not a guarantee of future
performance or developments. You are strongly cautioned that reliance on any forward-looking
statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any
of these forward-looking statements. There are many important factors that could cause our actual
results and financial condition to differ materially from those indicated in the forward-looking statements,
including, but not limited to: the failure to obtain necessary regulatory and shareholder approvals for the
proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more
difficult to maintain business and operational relationships; significant transaction costs and unknown
liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the
proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the
Company; the potential impact of laws or government regulations or policies in South Africa, the United
Kingdom or elsewhere; our reliance on the efforts of third parties; our future capital requirements and
sources and uses of cash; our ability to obtain funding for our operations and future growth; our reliance
on the efforts of third parties; our ability to complete the construction and commissioning of our
enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment
Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the
financial terms of any current and future commercial arrangements; our ability to complete certain
transactions and realize anticipated benefits from acquisitions and contracts; dependence on our
Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry;
and the factors disclosed in Part I, Item 1A. "Risk Factors" of the company's Annual Report on Form
10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company's
subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking
statement made by us in this press release is based only on information currently available to us and
speaks only as of the date on which it is made. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information, future developments or otherwise.
This press release includes market and industry data and forecasts that we obtained from internal
research, publicly available information and industry publications and surveys. Industry publications and
surveys generally state that the information contained therein has been obtained from sources believed
to be reliable. Unless otherwise noted, statements as to our potential market position relative to other
companies are approximated and based on third-party data and internal analysis and estimates as of
the date of this press release. We have not independently verified this information, and it could prove
inaccurate. Industry and market data could be wrong because of the method by which sources obtained
their data and because information cannot always be verified with certainty due to the limits on the
availability and reliability of raw data, the voluntary nature of the data-gathering process and other
limitations and uncertainties. In addition, we do not know all of the assumptions regarding general
economic conditions or growth that were used in preparing the information and forecasts from sources
cited herein. No information in this press release should be interpreted as an indication of future
success, revenues, results of operation, or stock price. All forward-looking statements herein are
qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
30 September 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 30-09-2025 02:18:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
